Key facts
- US scrutiny of investment and technology transfers complicates cross-border biotech deals.
- Western pharmaceutical companies are expected to continue partnering with Chinese biotech firms.
- Germany has warned the US that a drug pricing probe may endanger an EU-US trade deal.
- The prospective EU-US trade deal anticipates a tariff ceiling of 15 percent.
Cross-border biotech deals between the United States and China are encountering increased complexity and a potential slowdown due to heightened US scrutiny on investment and technology transfers, industry analysts report. This increased oversight is creating regulatory hurdles for collaborations. Despite these challenges, the trend of Western pharmaceutical companies partnering with Chinese biotech firms is expected to continue and potentially accelerate.